Coenzyme Q10 treatment for heart disease

Treatment Protocol

Group A: Intravenous infusion of fructose diphosphate sodium at a daily dose of 100-250 mg/kg and vitamin C at a dose of 100 mg/kg per day. Group B: Oral administration of coenzyme Q10 tablets at a dose of 10 mg per dose, three times a day, and intravenous infusion of sodium phosphate creatine at a dose of 50 mg (kg·day). Both groups of patients received comprehensive treatment, which included bed rest, oxygen therapy, a high-nutrition high-protein diet, antiarrhythmic medications, anti-inflammatory steroids, and electrolyte balance management.

Coenzyme Q10 treatment for heart disease-Xi'an Lyphar Biotech Co., Ltd

Observation Indicators

The observation indicators in this study included the time of disappearance of clinical symptoms, myocardial enzyme spectrum (including creatine kinase, creatine kinase isoenzyme, troponin I, lactate dehydrogenase, and hydroxybutyrate dehydrogenase), and immune function indicators (CD3+, CD4+, CD8+).

Research Results

The results of the study showed that the overall effective rate of treatment in Group B was significantly higher than that in Group A (P<0.05), and the time for clinical symptoms to disappear in Group B was significantly shorter than that in Group A. Furthermore, the levels of myocardial enzyme spectrum after treatment were significantly lower in Group B compared to Group A, and the immune function indicators were significantly higher in Group B than in Group A. The incidence of complications did not show a significant difference between the two groups.


In summary, the treatment of pediatric viral myocarditis with the combination of coenzyme Q10 and sodium phosphate creatine can effectively reduce the levels of the myocardial enzyme spectrum, protect myocardial cells, improve immune function, and promote the recovery of the condition.